论文部分内容阅读
本文对慢性肝炎、肝硬化、肝癌及输血史患者血清进行抗丙型肝炎病毒抗体测定及慢性肝病免疫指标观察分析,146例慢性肝病及输血史患者抗-HCV阳性率为52.7％(77/146),HBsAg和抗-HCV双阳性率为18.5％(27/146)。3种肝病患者抗-HCV及HBsAg阳性结果分析表明,HBsAg阳性率无明显差异,而抗-HCV阳性率肝硬化和肝癌明显高于慢性肝炎。HCV引起的慢性肝病IgG、IgA明显增高。预防输血后肝炎,减少HCV对血液的污染是重要一环。
In this paper, the serum of patients with chronic hepatitis, cirrhosis, liver cancer and blood transfusion were tested for anti-HCV antibody and immune indicators of chronic liver disease. The positive rate of anti-HCV in 146 patients with chronic liver disease and blood transfusion was 52.7% (77/146 ), HBsAg and anti-HCV double positive rate was 18.5% (27/146). Anti-HCV and HBsAg positive results of 3 kinds of liver disease patients showed no significant difference in the positive rate of HBsAg, but the positive rate of anti-HCV positive cirrhosis and liver cancer was significantly higher than that of chronic hepatitis. HCV-induced chronic liver disease IgG, IgA was significantly higher. Prevention of post-transfusion hepatitis, reducing HCV blood pollution is an important part.